FDA Grants Fast Track Designation to VectorY’s VTx-002 AAV Gene Therapy for the Treatment of ALS

AMSTERDAM & BOSTON —January 08, 2026— VectorY Therapeutics, a pioneer in the development of next-generation AAV gene delivery, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to VTx-002. This first-in-class AAV-vectorized antibody therapy is designed to address the underlying pathology of Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative condition.

Vectorized AAV Precision for TDP-43 Pathology

The breakthrough treatment utilizes a specialized AAV5 capsid to deliver a genetic blueprint directly to the central nervous system. Once the AAV vector enters the target cells, it enables the continuous production of therapeutic antibodies designed to clear toxic TDP-43 protein aggregates—the pathological hallmark present in approximately 97% of all ALS cases.

Unlike traditional systemic antibody infusions, this AAV-based approach provides:

• One-Time Delivery: A single administration into the cerebrospinal fluid ensures long-term therapeutic expression.

• Intracellular Targeting: The AAV payload allows antibodies to be produced inside the neurons, where the toxic protein clumps actually form.

• Safety Profile: The AAV5 serotype was selected for its proven clinical safety and its ability to achieve broad distribution throughout the brain and spinal cord.

Accelerated Clinical Path via AAV Advancement

The Fast Track Designation follows the recent FDA clearance of the Investigational New Drug (IND) application for VTx-002. This regulatory milestone allows VectorY to move forward with PIONEER-ALS, a Phase 1/2 study that will evaluate the safety and pharmacodynamic activity of the AAV candidate.

“The FDA’s decision to grant Fast Track designation to VTx-002 underscores the importance of advancing new AAV-mediated investigational approaches,” said Jim Scibetta, CEO of VectorY. “This enables more frequent interaction with the FDA as we prepare to dose our first patient in early 2026.”

By leveraging the unique strengths of AAV technology, VectorY aims to shift the treatment paradigm for ALS from symptomatic management to disease modification, offering hope to the more than 30,000 Americans currently living with the disease.